Segment comparison
J&J's Innovative Medicine vs Pfizer's Biopharma segment revenue from SEC filings. Pfizer reports as a single operating segment, so Biopharma is all of Pfizer.
Innovative Pharma Revenue: J&J vs Pfizer, annual revenue, 2022–2025. JNJ — Innovative Medicine: latest $60.4B (Dec 28, 2025).
| Company | Segment | Latest annual | Period end |
|---|---|---|---|
| JNJ JOHNSON & JOHNSON | Innovative Medicine | $60.4B | Dec 28, 2025 |
Revenue concepts only: a member is charted only when its underlying XBRL concept is revenue and its dimension type is chart-eligible — member mapping alone is not enough. Each company's latest annual period is its own fiscal year (fiscal years differ: e.g. Target's FY2026 ends 2026-01-31, Broadcom's FY2025 ends 2025-11-02). Rollup parents and children are never charted together; multi-dimension leaves are charted as their own series; geography buckets are exposure comparisons and never sum to a world total.
Pfizer reports as a single operating segment, so Biopharma is all of Pfizer; J&J's Innovative Medicine excludes MedTech.
Segment figures come from SEC EDGAR filings. Fiscal years differ by company. Informational only, not investment advice.